• 1
    Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med 1998; 338: 853860.
  • 2
    Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356: 14231430.
  • 3
    Hammer SM, Eron JJ Jr, Reiss P et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300: 555570.
  • 4
    Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001; 15: 7175.
  • 5
    Cespedes MS, Aberg JA. Neuropsychiatric complications of antiretroviral therapy. Drug Saf 2006; 29: 865874.
  • 6
    Caso JA, Prieto Jde M, Casas E, Sanz J. Gynecomastia without lipodystrophy syndrome in HIV-infected men treated with efavirenz. AIDS 2001; 15: 14471448.
  • 7
    Mercie P, Viallard JF, Thiebaut R et al. Efavirenz-associated breast hypertrophy in HIV-infection patients. AIDS 2001; 15: 126129.
  • 8
    Rahim S, Ortiz O, Maslow M, Holzman R. A case-control study of gynecomastia in HIV-1-infected patients receiving HAART. AIDS Read 2004; 14: 2324, 29–32, 35–40.
  • 9
    Manfredi R, Calza L, Chiodo F. Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study. J Acquir Immune Defic Syndr 2004; 35: 492502.
  • 10
    Jover F, Cuadrado JM, Roig P, Rodriguez M, Andreu L, Merino J. Efavirenz-associated gynecomastia: report of five cases and review of the literature. Breast J 2004; 10: 244246.
  • 11
    Mira JA, Lozano F, Santos J et al. Gynaecomastia in HIV-infected men on highly active antiretroviral therapy: association with efavirenz and didanosine treatment. Antivir Ther 2004; 9: 511517.
  • 12
    Sikora MJ, Cordero KE, Larios JM, Johnson MD, Lippman ME, Rae JM. The androgen metabolite 5alpha-androstane-3beta,17beta-diol (3betaAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance. Breast Cancer Res Treat 2009; 115: 289296.
  • 13
    Stahle L, Moberg L, Svensson JO, Sonnerborg A. Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects. Ther Drug Monit 2004; 26: 267270.
  • 14
    Dobrzycka KM, Townson SM, Jiang S, Oesterreich S. Estrogen receptor corepressors – a role in human breast cancer? Endocr Relat Cancer 2003; 10: 517536.
  • 15
    Shiels MS, Cole SR, Kirk GD, Poole C. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr 2009; 52: 611622.
  • 16
    Kegg S, Lau R. Tamoxifen in antiretroviral-associated gynaecomastia. Int J STD AIDS 2002; 13: 582583.
  • 17
    Perdona S, Autorino R, De Placido S et al. Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial. Lancet Oncol 2005; 6: 295300.
  • 18
    Fradet Y, Egerdie B, Andersen M et al. Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study. Eur Urol 2007; 52: 106114.
  • 19
    Johnson MD, Zuo H, Lee KH et al. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 2004; 85: 151159.
  • 20
    Rae JM, Johnson MD, Scheys JO, Cordero KE, Larios JM, Lippman ME. GREB 1 is a critical regulator of hormone dependent breast cancer growth. Breast Cancer Res Treat 2005; 92: 141149.
  • 21
    Rae JM, Lippman ME. Evaluation of novel epidermal growth factor receptor tyrosine kinase inhibitors. Breast Cancer Res Treat 2004; 83: 99107.